World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

What makes us special?

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

What makes us special?

Richmond Pharmacology delivers clinical excellence from design to delivery. Our long-term working relationships with our international client-base has led to the completion of over 500 Early Phase Studies.

We provide a personal service. Our founders are influential clinical research experts and lead each clinical trial. Our team of senior drug development experts are also on hand to ensure the quality, integrity, and accuracy of your study. We are reputed for our customer-centric project management, our flexible approach, and the superior quality of the studies. As a sponsor, you will have high-level engagement and meaningful peer to peer conversations.

Accredited by the MHRA, we guarantee that our trials adhere to the highest clinical, ethical and safety standards and our processes are auditable.

Our efficient and adaptive approach leads to faster development times, accelerating the time to market from first in human trials to proof of concept in under nine months. Adding value by integrating ethnic comparison elements and intensive cardiac assessments.


The clinical unit is in the heart of London with easy access to mainline train stations and airports, making it the ideal location to attract research volunteers.

Richmond Pharmacology’s volunteer database exceeds 250,000 individuals from a broad demographic spectrum and a wide variety of patient panels across rare to more common diseases. The database grows by 1000 to 2000 volunteers each month with a typical 70/30 split between healthy volunteers and patients.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more